Skip to Content
Merck

Alternative delivery of a thermostable inactivated polio vaccine.

Vaccine (2015-03-17)
Heleen Kraan, Ivo Ploemen, Gijsbert van de Wijdeven, Ivo Que, Clemens Löwik, Gideon Kersten, Jean-Pierre Amorij
ABSTRACT

In the near future oral polio vaccine (OPV) will be replaced by inactivated polio vaccine (IPV) as part of the eradication program of polio. For that reason, there is a need for substantial amount of safe and more affordable IPV for low-income countries. Bioneedles, which are biodegradable mini-implants, have the potential to deliver vaccines outside the cold-chain and administer them without the use of needles and syringes. In the current study, Bioneedles were filled with IPV, subsequently lyophilized, and antigenic recoveries were determined both directly after IPV-Bioneedle preparation as well as after elevated stability testing. Further, we assessed the immunogenicity of IPV-Bioneedles in rats and the residence time at the site of administration. Trivalent IPV was formulated in Bioneedles with recoveries of 101±10%, 113±18%, and 92±15%, respectively for serotypes 1, 2 and 3. IPV in Bioneedles is more resistant to elevated temperatures than liquid IPV: liquid IPV retained less than half of its antigenicity after 1 day at 45°C and IPV in Bioneedles showed remaining recoveries of 80±10%, 85±4% and 63±4% for the three serotypes. In vivo imaging revealed that IPV administered via Bioneedles as well as subcutaneously injected liquid IPV showed a retention time of 3 days at the site of administration. Finally, an immunogenicity study showed that IPV-filled Bioneedles are able to induce virus-neutralizing antibody titers similar to those obtained by liquid intramuscular injection when administered in a booster regime. The addition of LPS-derivate PagL in IPV-filled Bioneedles did not increase immunogenicity compared to IPV-Bioneedles without adjuvant. The current study demonstrates the pre-clinical proof of concept of IPV-filled Bioneedles as a syringe-free alternative delivery system. Further pre-clinical and clinical studies will be required to assess the feasibility whether IPV-Bioneedles show sufficient safety and efficacy, and may contribute to the efforts to eradicate and prevent polio in the future.

MATERIALS
Product Number
Brand
Product Description

Supelco
Sorbitol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D-Sorbitol, liquid, tested according to Ph. Eur.
Sigma-Aldrich
D-Sorbitol, BioUltra, ≥99.0% (HPLC)
Sigma-Aldrich
D-Sorbitol, FCC, FG
Sigma-Aldrich
D-Sorbitol, 99% (GC)
Sigma-Aldrich
Sorbitol F solution, 70 wt. % in H2O, Contains mainly D-sorbitol with lesser amounts of other hydrogenated oligosaccharides
Sigma-Aldrich
D-Sorbitol, ≥98% (GC)
Sigma-Aldrich
D-Sorbitol, ≥98% (GC), BioReagent, suitable for cell culture, suitable for plant cell culture
Sigma-Aldrich
D-Sorbitol, ≥98% (GC), BioXtra
Sigma-Aldrich
D-Sorbitol, ≥98% (GC), for molecular biology
Sorbitol, European Pharmacopoeia (EP) Reference Standard
USP
Sorbitol, United States Pharmacopeia (USP) Reference Standard
Supelco
Citric acid, Anhydrous, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Magnesium chloride hexahydrate, BioUltra, ≥99.0% (KT)
Sigma-Aldrich
Magnesium chloride hexahydrate, tested according to Ph. Eur.
Sigma-Aldrich
Magnesium chloride hexahydrate, BioUltra, for molecular biology, ≥99.0% (KT)
Sigma-Aldrich
Citric acid, BioUltra, anhydrous, ≥99.5% (T)
Sigma-Aldrich
Magnesium chloride hexahydrate, 99.995% trace metals basis
Sigma-Aldrich
Citric acid, ≥99.5%, FCC, FG
Sigma-Aldrich
Magnesium chloride hexahydrate, meets USP testing specifications
Sigma-Aldrich
Magnesium chloride hexahydrate, BioXtra, ≥99.0%
Sigma-Aldrich
Magnesium chloride hexahydrate, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Citric acid, anhydrous, suitable for cell culture, suitable for plant cell culture
Citric acid, anhydrous, European Pharmacopoeia (EP) Reference Standard
USP
Citric acid, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Magnesium chloride hexahydrate, ACS reagent, 99.0-102.0%
Sigma-Aldrich
Citric acid, ACS reagent, ≥99.5%
Sigma-Aldrich
2-Hydroxybutyric acid sodium salt, 97%
Sigma-Aldrich
Citric acid, 99%
Sigma-Aldrich
Citric acid, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99.5%